Bottles of "Holy Water" Contaminated With Cholera Send European Tourists to the ICU
Researchers are warning that bottles of "holy water" from a well in Ethiopia could be laced with dangerous bacteria that could cause cholera.
As detailed in a new report published in the journal Eurosurveillance and spotted by Ars Technica, three German and four British tourists developed a nasty case of cholera, a bacterial disease spread through contaminated water and food, after drinking or splashing their face with holy water from plastic bottles they had brought back to Europe after visiting the Quara district of Ethiopia.
The bottles of holy water were absolutely teeming with the bacteria Vibrio cholerae, per the report, with an estimated 100,000 to 100 million "colony forming units," which allowed the bacteria to remain "viable at ambient temperature during the flight and in Europe."
Two of the tourists required intensive care, but all eventually recovered from the unfortunate ordeal.
Per the US Centers for Disease Control and Prevention, cholera can cause severe diarrhea, dehydration, and in extreme cases death, if it goes untreated. Infection can be prevented by washing hands with soap, drinking treated water, and getting vaccinated against cholera.
The water was taken from a "holy well" called "Bermel Giorgis," near the border between Ethiopia and Sudan. The local Orthodox church claims the well is a revered holy site that "offers an unparalleled spiritual experience where visitors often gain clarity, healing, and a deeper connection to faith," according to a travel website.
But considering the nasty bacterial infection the tourists experienced, drinking the well's water appears to have some less-than-angelic side effects as well.
And according to a bulletin by the CDC published last month, more visitors could be at risk.
"Travellers to Ethiopia intending to visit the well, as well as friends and family who may be gifted bottles of water from the well, remain at risk until the source of contamination has been addressed," the bulletin reads.
Complicating matters is an ongoing armed conflict in the area, which could render "interventions to address the source of contamination currently challenging," per the CDC.
Worse yet, cholera deaths are back on the rise, according to the World Health Organization. The number of reported cases increased by 13 percent and deaths by 71 percent in 2023 compared to 2022. Over 4,000 people died from the disease in 2023, despite the widespread availability of highly effective treatments.
And the Trump administration's massive cuts to USAID have already made it more difficult for vulnerable people worldwide to access treatment for cholera.
As Al Jazeera reported this week, eight people, including five children, died in South Sudan after walking for three hours in extreme heat to seek treatment for the disease. Their local USAID health facilities were forced to close due to the agency's budget cuts.
More on cholera: 'Zombie' Deer Disease Could Spread to Humans, Experts Warn

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Trump's DOGE efficiency agency says it slashes $25B in federal spending as rehiring begins
The Department of Government Efficiency (DOGE) announced on Wednesday it has decreased its annual non-defense federal obligations by an additional ~1.9% since last month. As of June 8th, annual non-defense federal obligations are down 22.4%, or ~$25B, as compared to 2024, DOGE announced on X. The cut marks an additional ~1.9% reduction from last month's figures, which were announced on May 8. Doge's Greatest Hits: Look Back At The Department's Most High-profile Cuts During Trump's First 100 Days "Cash outlays will follow as obligations come due," DOGE wrote in the post. "Our initiative to reduce wasteful spend, consistent with the DOGE Cost Efficiency Executive Order, continues to bear fruit." On May 14, DOGE announced the current year's non-defense federal obligations were down 20.5% as compared to 2024. Read On The Fox News App The announcement came minutes before Fox News Digital was first to report the Department of Health and Human Services (HHS) is rehiring more than 450 previously fired employees belonging to multiple divisions within the agency's Centers for Disease Control and Prevention (CDC). The rehired CDC employees came from the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention; the National Center for Environmental Health; the Immediate Office of the Director, and the Global Health Center, according to an HHS official familiar with the matter. HHS Secretary Robert F. Kennedy Jr. told CBS News in April some personnel who were cut shouldn't have been. Doge Ends 108 'Wasteful' Contracts, Including For An 'Executive Transformational Leadership Training Program' "We're reinstating them, and that was always the plan," Kennedy said. "Part of the—at DOGE, we talked about this from the beginning, is we're going to do 80% cuts, but 20% of those are going to have to be reinstated, because we'll make mistakes." In addition to the HHS rehires, the Internal Revenue Service, Food and Drug Administration, State Department, and Department of Housing and Urban Development started rehiring employees let go during DOGE cuts, the Washington Post reported. Doge Takes A Chainsaw To Federal Spending With 7 Major Victories This Week: 'Got To Be Done' Another roadblock this week was a ruling from U.S. District Judge Denise Cote of the Southern District of New York, who ruled to restrict the agency's access to federal databases. The Trump administration previously said DOGE could not work effectively with the limitations, noting DOGE needed to access Social Security information to root out fraud. Fox News Digital's Alec Schemmel and Danielle Wallace contributed to this article source: Trump's DOGE efficiency agency says it slashes $25B in federal spending as rehiring begins
Yahoo
25 minutes ago
- Yahoo
Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)
Insmed Incorporated (NASDAQ:INSM) is among the 13 Biotech Stocks with Huge Upside Potential. Kelly Shi of Jefferies has given Insmed Incorporated (NASDAQ:INSM) a buy recommendation, stating that she is confident in the TPIP treatment's impending Phase 2 data for pulmonary arterial hypertension. A biopharmaceutical research team taking notes in front of a laboratory's microscope. Shi anticipates a substantial decrease in pulmonary vascular resistance, the main outcome of the trial, of 20%, which is regarded as a definite success. If the results are encouraging, TPIP may replace Tyvaso, the current standard treatment. On June 4, Wells Fargo reaffirmed its Buy recommendation, with a price objective of $107. Shi points out that TPIP's once-daily dosage is a significant benefit over Tyvaso's four-times-daily schedule, which could increase adherence and make it more appealing to patients as well as physicians. The efficacy potential of TPIP is supported by interim study results that show additional advantages in six-minute walk distance (6MWD). Shi expects significant market penetration in light of these considerations, which could lead to an increase in Insmed Incorporated (NASDAQ:INSM)'s valuation. Both analysts highlight that if future trial results live up to predictions, TPIP has the potential to completely change the way that PAHs are treated. Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm that improves the lives of individuals suffering from serious and rare diseases. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Vertex Presents New Data on the Benefits of ALYFTREK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 13 Biotech Stocks with Huge Upside Potential. The company shared new data at the 48th European Cystic Fibrosis Conference, revealing that ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) is linked with improved clinical outcomes and quality of life in cystic fibrosis (CF) patients. A pharmacist delivering a specific medication to a patient in a specialty pharmacy. A pooled research found that sweat chloride (SwCl) levels below 60 mmol/L were associated with improved lung function, fewer exacerbations, and better nutritional and quality of life outcomes. Even larger numerical improvements were observed for SwCl below 30 mmol/L. According to post hoc data from Phase 3 trials, ALYFTREK outperformed TRIKAFTA® in terms of health outcomes for adults, adolescents, and children aged 6 to 11. Approximately 109,000 people worldwide, 94,000 of whom live in North America, Europe, and Australia, have cystic fibrosis. The majority of patients have at least one F508del mutation, which is the result of mutations in the CFTR gene. TRIKAFTA® is being donated in 14 lower-income countries, and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) medications currently serve over 75,000 people in 60+ countries, or almost two-thirds of eligible patients. It is among the stocks with the biggest upside. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data